Russia’s sovereign wealth fund and Indian pharmaceutical firm Hetero have agreed to supply over 100 million doses per yr in India of the Sputnik V vaccine towards COVID-19, in keeping with a press release on the Sputnik V Twitter account on Friday.
Hetero and the Russian Direct Funding Fund (RDIF), which has been backing the vaccine and advertising it globally, plan to begin manufacturing of Sputnik V in India in the beginning of 2021, the assertion stated.
Part II-III trials are ongoing in India, the assertion stated. Drugmaker Dr Reddy’s Laboratories Ltd has stated it expects late-stage trials to be accomplished by as early as March 2021.
(Apart from the headline, this story has not been edited by NDTV workers and is printed from a syndicated feed.)